# Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine

> **NCT00485407** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 377 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Atomoxetine Hydrochloride

## Key facts

- **NCT ID:** NCT00485407
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** —
- **Final completion:** 2005-06
- **Target enrollment:** 377 (ACTUAL)
- **Last updated:** 2007-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485407, "Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00485407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*